ESC 365 - Transthyretin amyloid cardiomyopathy (ATTR-CM): suspicion starts with the patient

ESC Premium Access

Transthyretin amyloid cardiomyopathy (ATTR-CM): suspicion starts with the patient

Session: Looking to the future of identifying transthyretin amyloid cardiomyopathy

Topic: Diagnostic Methods

Speaker: Professor C. Rapezzi (Ferrara, IT)

Sponsored by Pfizer

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

28 presentations

1 follower

4 more presentations in this session

Introduction and welcome

Speaker: Professor T. Damy (Creteil, FR)

Confirming a suspicion of ATTR-CM: getting the diagnosis right

Speaker: Doctor P. Garcia-Pavia (Madrid, ES)

Panel discussion: no patient left behind

Speaker: Professor P. Elliott (London, GB) Professor T. Damy (Creteil, FR) Professor C. Rapezzi (Ferrara, IT) Doctor P. Garcia-Pavia (Madrid, ES)

Summary and symposium close

Speaker: Professor T. Damy (Creteil, FR)

Access the full session

Looking to the future of identifying transthyretin amyloid cardiomyopathy

Speakers: Professor C. Rapezzi, Professor T. Damy, Doctor P. Garcia-Pavia, Professor P. Elliott, Professor T. Damy...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

Open Access

Mode of intervention in mitral regurgitation.

28 August 2021

Open Access

Timing and indication of intervention in asymptomatic patients with valvular heart disease.

28 August 2021

ESC Premium Access

A comprehensive guide to risk stratification for sudden cardiac death in hypertrophic cardiomyopathy.

27 August 2021

ESC 365 is supported by